title: Geriatric considerations in the treatment of advanced prostate cancer.
abstract: Prostate cancer is the most common non-cutaneous cancer in US men and mainly affects elderly patients, with most new diagnoses occurring in those over 65. As the geriatric population in the US continues to grow, the incidence of this disease is likewise expected to rise. Many older patients are diagnosed with advanced disease or are treated only when their disease becomes symptomatic or metastatic. The treatment options for advanced prostate cancer have increased dramatically in the last decade. It is important to understand the nuances of caring for an elderly cancer patient in order to optimally treat prostate cancer, such as the importance of using a geriatric assessment to uncover overlooked or under-reported vulnerabilities. In addition, many of the newly approved agents for the treatment of advanced prostate cancer have a unique mechanism of action and toxicities that warrant consideration when choosing therapies for older patients. This review focuses on the importance of a geriatric assessment as well as the considerations of treating elderly patients with the newer agents approved for prostate cancer.
authors.affiliation: University of Colorado Cancer Center, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045 USA ; Division of Medical Oncology, School of Medicine, University of Colorado Denver, Anschutz Medical Campus Aurora, CO 80045 USA.
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Kessler
authors.affiliation: University of Colorado Cancer Center, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045 USA ; Division of Medical Oncology, School of Medicine, University of Colorado Denver, Anschutz Medical Campus Aurora, CO 80045 USA.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Flaig